Obesity and iron deficiency in chronic kidney disease: The putative role of hepcidin

Nephrology Dialysis Transplantation

Volumn 27, Issue 1, 2012, Pages 50-57

  Sarafidis, Pantelis A ^a   Rumjon, Adam ^a   MacLaughlin, Helen L ^a,b   MacDougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

hepcidin; inflammation; iron deficiency; kidney disease; obesity

Indexed keywords

HEPCIDIN; LEPTIN;

ADIPOSE TISSUE; ARTICLE; CAUSAL ATTRIBUTION; CHRONIC KIDNEY DISEASE; DIET THERAPY; DISEASE ASSOCIATION; FEEDBACK SYSTEM; HUMAN; IN VITRO STUDY; IRON DEFICIENCY; IRON METABOLISM; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; THERAPY EFFECT; WEIGHT REDUCTION;

ANEMIA, IRON-DEFICIENCY; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; HUMANS; KIDNEY FAILURE, CHRONIC; OBESITY; PROGNOSIS;

EID: 84856637021     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr686     Document Type: Article

References (65)

1. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 2007; 18: 394-400 (Pubitemid 46193304)
2. Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu Rev Pathol 2009; 4: 489-515
3. Park CH, Valore EV, Waring AJ et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810
4. Krause A, Neitz S, Magert HJ et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480: 147-150
5. Nicolas G, Bennoun M, Devaux I et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98: 8780-8785 (Pubitemid 32678104)
6. Pigeon C, Ilyin G, Courselaud B et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-7819
7. Macdougall IC, Malyszko J, Hider RC et al. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 1681-1689
8. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093 (Pubitemid 40007660)
9. Drakesmith H, Schimanski LM, Ormerod E et al. Resistance to hep-cidin is conferred by hemochromatosis-associated mutations of ferro-portin. Blood 2005; 106: 1092-1097 (Pubitemid 41076459)
10. Chaston T, Chung B, Mascarenhas M et al. Evidence for differential effects of hepcidin in macrophages and intestinal epithelial cells. Gut 2008; 57: 374-382 (Pubitemid 351288105)
11. Mena NP, Esparza AL, Nunez MT. Regulation of transepithelial transport of iron by hepcidin. Biol Res 2006; 39: 191-193 (Pubitemid 44027661)
12. Mena NP, Esparza A, Tapia V et al. Hepcidin inhibits apical iron uptake in intestinal cells. Am J Physiol Gastrointest Liver Physiol 2008; 294: G192-G198
13. Brasse-Lagnel C, Karim Z, Letteron P et al. Intestinal DMT1 cotrans-porter is down-regulated by hepcidin via proteasome internalization and degradation. Gastroenterology 2011; 140: 1261-1271.e1
14. Fleming MD. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program 2008; 151-158
15. Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-1044
16. Lee P, Peng H, Gelbart T et al. The IL-6-and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci USA 2004; 101: 9263-9265 (Pubitemid 38812863)
17. Nemeth E, Valore EV, Territo M et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463 (Pubitemid 36857598)
18. Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer 2006; 46: 554-557
19. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009; 1790: 682-693
20. Costa E, Swinkels DW, Laarakkers CM et al. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hae-modialysis patients. Acta Haematol 2009; 122: 226-229
21. Weiss G, Theurl I, Eder S et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009; 39: 883-890
22. McClung JP, Karl JP. Iron deficiency and obesity: the contribution of inflammation and diminished iron absorption. Nutr Rev 2009; 67: 100-104
23. Zafon C, Lecube A, Simo R. Iron in obesity. An ancient micronutrient for a modern disease. Obes Rev 2010; 11: 322-328
24. Lago F, Dieguez C, Gomez-Reino J et al. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007; 18: 313-325 (Pubitemid 46891288)
25. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008; 118: 2992-3002
26. Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypertens 2006; 24: 621-626
27. Sarafidis PA. Metabolic syndrome and arterial stiffness: evidence for gender disparity and early effects of non-traditional risk factors? J Hypertens 2007; 25: 935-938 (Pubitemid 46573109)
28. Bray GA, Wilson JF. In the clinic. Obesity. Ann Intern Med 2008; 149: ITC4-ITC15
29. Ludwig DS. Childhood obesity-the shape of things to come. N Engl J Med 2007; 357: 2325-2327 (Pubitemid 350223386)
30. Pollitt E. Iron deficiency and cognitive function. Annu Rev Nutr 1993; 13: 521-537 (Pubitemid 23227795)
31. Wenzel BJ, Stults HB, Mayer J. Hypoferraemia in obese adolescents. Lancet 1962; 2: 327-328
32. Seltzer CC, Mayer J. Serum iron and iron-binding capacity in adolescents. II. Comparison of obese and nonobese subjects. Am J Clin Nutr 1963; 13: 354-361
33. Nead KG, Halterman JS, Kaczorowski JM et al. Overweight children and adolescents: a risk group for iron deficiency. Pediatrics 2004; 114: 104-108 (Pubitemid 38857573)
34. Pinhas-Hamiel O, Newfield RS, Koren I et al. Greater prevalence of iron deficiency in overweight and obese children and adolescents. Int J Obes Relat Metab Disord 2003; 27: 416-418 (Pubitemid 36384882)
35. Chambers EC, Heshka S, Gallagher D et al. Serum iron and body fat distribution in a multiethnic cohort of adults living in New York City. J Am Diet Assoc 2006; 106: 680-684
36. Yanoff LB, Menzie CM, Denkinger B et al. Inflammation and iron deficiency in the hypoferremia of obesity. Int J Obes (Lond) 2007; 31: 1412-1419 (Pubitemid 47339930)
37. Ausk KJ, Ioannou GN. Is obesity associated with anemia of chronic disease? A population-based study. Obesity (Silver Spring) 2008; 16: 2356-2361
38. Lecube A, Carrera A, Losada E et al. Iron deficiency in obese postmenopausal women. Obesity (Silver Spring) 2006; 14: 1724-1730 (Pubitemid 46214794)
39. Zimmermann MB, Zeder C, Muthayya S et al. Adiposity in women and children from transition countries predicts decreased iron absorption, iron deficiency and a reduced response to iron fortification. Int J Obes (Lond) 2008; 32: 1098-1104 (Pubitemid 351986198)
40. Gillum RF. Association of serum ferritin and indices of body fat distribution and obesity in Mexican American men-the Third National Health and Nutrition Examination Survey. Int J Obes Relat Metab Disord 2001; 25: 639-645 (Pubitemid 32417632)
41. Iwasaki T, Nakajima A, Yoneda M et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care 2005; 28: 2486-2491 (Pubitemid 41384298)
42. Wrede CE, Buettner R, Bollheimer LC et al. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol 2006; 154: 333-340
43. Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev 2007; 6: 457-463 (Pubitemid 47079115)
44. Hassapidou M, Fotiadou E, Maglara E et al. Energy intake, diet composition, energy expenditure, and body fatness of adolescents in northern Greece. Obesity (Silver Spring) 2006; 14: 855-862 (Pubitemid 46219727)
45. Menzie CM, Yanoff LB, Denkinger BI et al. Obesity-related hypo-ferremia is not explained by differences in reported intake of heme and nonheme iron or intake of dietary factors that can affect iron absorption. J Am Diet Assoc 2008; 108: 145-148 (Pubitemid 350301976)
46. Failla ML, Kennedy ML, Chen ML. Iron metabolism in genetically obese (ob/ob) mice. J Nutr 1988; 118: 46-51 (Pubitemid 18053346)
47. Komolova M, Bourque SL, Nakatsu K et al. Sedentariness and increased visceral adiposity in adult perinatally iron-deficient rats. Int J Obes (Lond) 2008; 32: 1441-1444
48. McClung JP, Andersen NE, Tarr TN et al. Physical activity prevents augmented body fat accretion in moderately iron-deficient rats. J Nutr 2008; 138: 1293-1297 (Pubitemid 351930992)
49. Babitt JL, Huang FW, Wrighting DM et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006; 38: 531-539
50. Verga Falzacappa MV, Vujic SM, Kessler R et al. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007; 109: 353-358 (Pubitemid 46053077)
51. Bekri S, Gual P, Anty R et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006; 131: 788-796 (Pubitemid 44316823)
52. Vokurka M, Lacinova Z, Kremen J et al. Hepcidin expression in adipose tissue increases during cardiac surgery. Physiol Res 2010; 59: 393-400
53. Ye J, Gao Z, Yin J et al. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007; 293: E1118-E1128 (Pubitemid 47535846)
54. Hintze KJ, Snow D, Nabor D et al. Adipocyte hypoxia increases hepatocyte hepcidin expression. Biol Trace Elem Res 2011; 143: 764-771
55. Chung B, Matak P, McKie AT et al. Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J Nutr 2007; 137: 2366-2370 (Pubitemid 350058702)
56. Malyszko J. Hemojuvelin: the hepcidin story continues. Kidney Blood Press Res 2009; 32: 71-76
57. Lin L, Nemeth E, Goodnough JB et al. Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells Mol Dis 2008; 40: 122-131 (Pubitemid 350193320)
58. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008; 111: 924-931
59. Luciani N, Brasse-Lagnel C, Poli M et al. Hemojuvelin: a new link between obesity and iron homeostasis. Obesity (Silver Spring) 2011; 19: 1545-1551
60. del Giudice EM, Santoro N, Amato A et al. Hepcidin in obese children as a potential mediator of the association between obesity and iron deficiency. J Clin Endocrinol Metab 2009; 94: 5102-5107
61. Aeberli I, Hurrell RF, Zimmermann MB. Overweight children have higher circulating hepcidin concentrations and lower iron status but have dietary iron intakes and bioavailability comparable with normal weight children. Int J Obes (Lond) 2009; 33: 1111-1117
62. Tussing-Humphreys LM, Nemeth E, Fantuzzi G et al. Elevated systemic hepcidin and iron depletion in obese premenopausal females. Obesity (Silver Spring) 2010; 18: 1449-1456
63. Amato A, Santoro N, Calabro P et al. Effect of body mass index reduction on serum hepcidin levels and iron status in obese children. Int J Obes (Lond) 2010; 34: 1772-1774
64. Tussing-Humphreys LM, Nemeth E, Fantuzzi G et al. Decreased serum hepcidin and improved functional iron status 6 months after restrictive bariatric surgery. Obesity (Silver Spring) 2010; 18: 2010-2016
65. Tussing-Humphreys L, Pini M, Ponemone V et al. Suppressed cytokine production in whole blood cultures may be related to iron status and hepcidin and is partially corrected following weight reduction in morbidly obese pre-menopausal women. Cytokine 2011; 53: 201-206